INIS
biological markers
50%
growth
25%
metastases
50%
mutations
50%
osteosarcomas
100%
patients
50%
refractories
100%
skin
25%
suppression
25%
therapy
25%
toxicity
50%
tumors
25%
Nursing and Health Professions
A Wave
25%
Adverse Event
25%
Biological Marker
50%
Combination Therapy
25%
Neoplasm
25%
Nomenclature
25%
Osteosarcoma
100%
Patient
100%
Recurrent Disease
25%
Skin Toxicity
25%
Sorafenib
100%
Toxicity
25%
Medicine and Dentistry
Adverse Event
25%
Biological Marker
50%
Combination Therapy
25%
Growth Inhibition
25%
Neoplasm
25%
Osteosarcoma
100%
Recurrent Disease
25%
Skin Toxicity
25%
Somatics
25%
Sorafenib
100%
Specimen
25%
Toxicity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Biological Marker
50%
Neoplasm
25%
Osteosarcoma
100%
Recurrent Disease
25%
Skin Toxicity
25%
Sorafenib
100%
Toxicity
25%
Veterinary Science and Veterinary Medicine